TETRANITE Bone Adhesive Expands Patent Portfolio with Innovative Injectable Composition 

The United States Patent and Trademark Office (USPTO) recently granted patent number 12,178,937, titled “Compositions and Methods for Adhesion to Surfaces,” marking the 10th U.S. patent for RevBio’s TETRANITE bone adhesive technology. This latest patent extends the scope of protected technology to include injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate. This development complements RevBio’s existing U.S. patent 11,638,777, which covers methods for repairing fractured bones using the adhesive composition. Together, these patents significantly bolster RevBio’s intellectual property portfolio in the field of bone repair. 

TETRANITE stands out as the only patented bone adhesive to incorporate phosphoserine, an organic compound demonstrated in scientific literature to actively participate in bone regeneration. This unique combination of mineral and organic components positions TETRANITE as a groundbreaking biomaterial with exceptional handling properties, weight-bearing strength, biocompatibility, and regenerative capabilities. 

George Kay, DMD, Chief Scientific Officer and co-founder of RevBio, emphasized the significance of this patent: “The granting of this patent continues to expand RevBio’s controlling intellectual property estate in the mineral-organic bone adhesive space. This novel and very promising biomaterial distinctively combines excellent handling characteristics, weight-bearing strength, and high biocompatibility with unique adhesive and bone regenerative properties.” 

RevBio, previously known as LaunchPad Medical, holds an exclusive worldwide patent license from Stryker Corporation (NYSE: SYK) for six patent families related to the bone adhesive technology. These patents, which cover both the composition and specific applications of the adhesive, provide protection through 2033, offering RevBio ample time to develop and commercialize TETRANITE-based products. 

Since 2016, RevBio has filed fourteen Patent Cooperation Treaty (PCT) applications to further protect and expand its patent portfolio. Many of these patents are expected to provide coverage through 2043. Four of these applications have already been issued as U.S. patents, while others are in various stages of prosecution in jurisdictions such as the European Union, Canada, Australia, Japan, and China. This extensive patent coverage supports RevBio’s product pipeline, including derivatives of the original TETRANITE adhesive, expanded methods of use, ancillary devices, and key packaging components. 

Brian Hess, CEO and founder of RevBio, highlighted the strategic importance of this new patent: “As a clinical-stage company, it is exciting to receive this key patent that expands patent protection for the full spectrum of indications we are pursuing. This new patent will enhance the company’s core value and competitive advantage for our investors who are funding the development of this game-changing technology platform.” 

Commentary by SuppBase columnist Alice Winters

RevBio’s TETRANITE bone adhesive technology represents a significant advancement in the field of bone repair and regeneration. The recent issuance of patent 12,178,937 underscores the company’s commitment to innovation and its strategic focus on expanding its intellectual property portfolio. This injectable mineral-organic adhesive, enriched with alpha tricalcium phosphate and phosphoserine, is a testament to the convergence of materials science and biomedical engineering. 

Ingredient Analysis and Formulation 

The inclusion of phosphoserine in TETRANITE is particularly noteworthy. Phosphoserine is an organic compound that plays a critical role in bone regeneration by promoting cell adhesion and mineralization. When combined with alpha tricalcium phosphate, a well-known bone graft material, the resulting adhesive exhibits both mechanical strength and biological activity. This dual functionality addresses a longstanding challenge in bone repair: achieving both structural stability and regenerative potential. 

Efficacy and Health Benefits 

TETRANITE’s unique formulation offers several advantages over traditional bone repair methods. Its injectable nature allows for minimally invasive application, reducing surgical complexity and patient recovery time. Additionally, its adhesive properties eliminate the need for mechanical fasteners, such as screws or plates, which can cause stress shielding and other complications. The material’s biocompatibility and regenerative capabilities further enhance its appeal, making it a promising solution for a wide range of orthopedic and dental applications. 

Market Feedback and Trends 

RevBio’s extensive patent portfolio and strategic licensing agreements position the company as a leader in the bone adhesive market. The growing demand for minimally invasive surgical techniques and bioactive materials aligns well with TETRANITE’s value proposition. Furthermore, the company’s focus on securing international patent protection reflects a forward-thinking approach to global market expansion. 

Safety and Dosage Considerations 

While TETRANITE’s biocompatibility is a significant advantage, further clinical studies are needed to fully assess its long-term safety and optimal dosage. As with any biomaterial, potential side effects, such as immune responses or unintended interactions with surrounding tissues, must be carefully evaluated. 

Environmental Impact and Packaging 

RevBio’s commitment to sustainability is evident in its efforts to patent key packaging components. As the healthcare industry increasingly prioritizes environmental responsibility, innovations in eco-friendly packaging could further enhance TETRANITE’s market appeal. 

Target Audience and Price 

TETRANITE is likely to appeal to both medical professionals and patients seeking advanced bone repair solutions. Its minimally invasive application and regenerative properties make it particularly suitable for elderly patients or those with compromised bone health. However, the cost of production and market pricing will play a critical role in determining its accessibility. 

Brand Credibility and Positioning 

RevBio’s collaboration with Stryker Corporation and its robust patent portfolio lend significant credibility to the TETRANITE brand. The company’s emphasis on innovation and strategic growth positions it as a key player in the biomaterials market. 

In conclusion, TETRANITE bone adhesive represents a transformative advancement in bone repair technology. Its unique formulation, combined with RevBio’s strategic intellectual property management, positions it as a game-changing solution with significant market potential. As the company continues to advance its clinical development and expand its global footprint, TETRANITE is poised to set a new standard in bone regeneration and repair.